SCHEMBL2535170

SCHEMBL2535170

Clc1ccc2nc(Cl)cc(Cl)c2c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.46
ALDH1A1 P00352 3/20 0.43
ACHE P22303 5/20 0.42
BCHE P06276 4/20 0.42
GRIN1 Q05586 4/20 0.42
GRIN2A Q12879 4/20 0.42
HIF1A Q16665 2/20 0.42
KDM4E B2RXH2 2/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2C19 P33261 1/20 0.42
NR4A2 P43354 1/20 0.41
HPGD P15428 2/20 0.41
NPC1 O15118 1/20 0.41
MAPK1 P28482 1/20 0.41
HTT P42858 1/20 0.41
RAB9A P51151 1/20 0.41
PTGES O14684 1/20 0.41
ALOX5 P09917 1/20 0.41
CYP2C9 P11712 1/20 0.41
CASP7 P55210 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29799170 1.00 LMNA (0.46) LMNAALDH1A1ACHEBCHEGRIN1
SCHEMBL30415489 0.83 POLB (0.50) ALDH1A1ACHEBCHENR4A2ESR1
SCHEMBL5638415 0.83 POLB (0.50) ALDH1A1ACHEBCHENR4A2ESR1
SCHEMBL23202873 0.82 AHR (0.44) ALDH1A1KDM4EHPGDNPC1MAPK1
SCHEMBL30827892 0.82 AHR (0.44) ALDH1A1KDM4EHPGDNPC1MAPK1
SCHEMBL5433753 0.79 NT5E (0.46) LMNAACHEBCHEGRIN1GRIN2A
SCHEMBL12598496 0.79 MAPT (0.46) LMNAALDH1A1ACHEHIF1AKDM4E
SCHEMBL7692119 0.79 ESR1 (0.64) LMNAALDH1A1ACHEHIF1AKDM4E
SCHEMBL20680332 0.79 LMNA (0.43) LMNAHIF1AKDM4ECYP3A4CYP2C19
SCHEMBL31218411 0.79 NT5E (0.64) LMNAACHEBCHEGRIN1GRIN2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12404249-B2 Heterocyclic derivatives and use thereof C&C RESEARCH LABORATORIES (KR) 2025-09-02 US disclosed
EP-3802495-B1 4-(2-((2-CHLOROQUINOLIN-4-YL)AMINO)ETHYL)BENZENESULFONAMIDE DERIVATIVES AS STAT3 INHIBITORS FOR THE TREATMENT OF CANCER C&C RES LAB (KR) 2025-07-02 EP disclosed
CN-112204010-B Heterocyclic derivatives and uses thereof C&C新药研究所 2024-03-19 CN disclosed
US-RE49481-E1 Compounds for the treatment and prophylaxis of respiratory syncytial virus disease HOFFMANN-LA ROCHE INC. (US) 2023-04-04 US disclosed
US-20210155594-A1 HETEROCYCLIC DERIVATIVES AND USE THEREOF C&C RESEARCH LABORATORIES (KR) 2021-05-27 US disclosed
EP-3802495-A1 HETEROCYCLIC DERIVATIVES AND USE THEREOF C&C Research Laboratories (KR) 2021-04-14 EP disclosed
CN-112204010-A Heterocyclic derivatives and use thereof C&C新药研究所 2021-01-08 CN disclosed
CN-103717589-B For treating or prevent the compound of respiratory syncytial virus disease 弗·哈夫曼-拉罗切有限公司 2016-08-17 CN disclosed
EP-2742039-B1 COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS DISEASE HOFFMANN LA ROCHE (CH) 2015-09-16 EP disclosed
US-9006281-B2 Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders ARDELYX, INC. (US) 2015-04-14 US disclosed
WO-2013020993-A1 COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS DISEASE F. HOFFMANN-LA ROCHE AG (CH) 2013-02-14 WO disclosed
US-8044068-B2 Aminopyrrolidine compound TAISHO PHARMACEUTICAL CO., LTD (JP) 2011-10-25 US disclosed
US-20090291940-A1 AMINOPYRROLIDINE COMPOUND TAISHO PHARMACEUTICAL CO., LTD. (JP) 2009-11-26 US disclosed
EP-2003131-A1 AMINOPYRROLIDINE COMPOUND Taisho Pharmaceutical Co. Ltd. (JP) 2008-12-17 EP disclosed
WO-2002026713-A1 ANTIPARASITIC COMPOUNDS KING'S COLLEGE LONDON (GB) 2002-04-04 WO disclosed
US-6046206-A Method of treating a patient having a precancerous lesions with amide quinazoline derivatives CELL PATHWAYS, INC. (US) 2000-04-04 US disclosed
US-5801180-A ANTIISCHEMIC AGENTS AND CARDIOVASCULAR DISORDERS EISAI CO., LTD. (JP) 1998-09-01 US disclosed
US-5693652-A Benzimidazoles for ischemic heart conditions EISAI CO., LTD. (JP) 1997-12-02 US disclosed
US-5576322-A Anti-ischemic 2,4-diaminoquinazolines EISAI CO., LTD. (JP) 1996-11-19 US disclosed
EP-0607439-A1 NITROGENOUS HETEROCYCLIC COMPOUND Eisai Co., Ltd. (JP) 1994-07-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090291940-A1 AMINOPYRROLIDINE COMPOUND MC4R, MC5R, MC2R LMNA 4408/4885ALDH1A1 2275/4885ACHE 1219/4885
US-20210155594-A1 HETEROCYCLIC DERIVATIVES AND USE THEREOF STAT3, JAK2, IRF3 LMNA 3057/4885ALDH1A1 1899/4885ACHE 4845/4885
US-12404249-B2 Heterocyclic derivatives and use thereof STAT3, JAK2, IRF3 LMNA 3057/4885ALDH1A1 1899/4885ACHE 4845/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.